论文部分内容阅读
肺癌是全球最常见的恶性肿瘤之一,也是我国目前的第一大癌。肺癌不仅发病率高,居恶性肿瘤首位,其死亡率也位列第一[1]。肺癌的5年生存率大概只有15%,约85%的肺癌为非小细胞肺癌,其发病机制至今尚未完全阐明。因此,非小细胞肺癌的早期预测和发现对于提高患者的治疗效果和预后显得非常重要。最近研究显示C4.4A作为膜蛋白受体的LY6家族的一个成员其调节异常和过度表达与多种肿瘤发生相关,其中,有研究发现C4.4A参与了非小细胞肺癌的浸润和转移。同时,有间接证据表明C4.4A与抑癌基因LKB1存在负向调控关系。因此,本文将围绕C4.4A在非小细胞肺癌中的研究进行简要的总结。
Lung cancer is one of the most common malignant tumors in the world and is the largest cancer in our country at present. Not only the high incidence of lung cancer, ranking first in malignant tumors, the mortality rate also ranked first [1]. The 5-year survival rate of lung cancer is only about 15%, about 85% of lung cancer is non-small cell lung cancer, the pathogenesis has not been fully elucidated. Therefore, the early prediction and detection of non-small cell lung cancer is very important for improving the therapeutic effect and prognosis of patients. Recent studies have shown that C4.4A is a member of the LY6 family of membrane protein receptors whose dysregulation and overexpression are associated with a variety of oncogenesis. It has been reported that C4.4A is involved in infiltration and metastasis of non-small cell lung cancer. At the same time, there is indirect evidence that C4.4A negatively regulates the tumor suppressor gene LKB1. Therefore, this article will focus on C4.4A in non-small cell lung cancer in a brief summary.